New ALS Treatment, AMX0035, No Evidence of Benefit, FDA Panel
[ad_1] The primary goal was to slow the decline. 48-point ALS scale Rate 12 physical abilities, including walking, speaking, swallowing, dressing, handwriting and breathing. Over the 24 weeks, patients who took the placebo dropped 2.32 points more than those who took the drug combination, resulting in a 25 percent slower decline in the treated patients …
Continue reading “New ALS Treatment, AMX0035, No Evidence of Benefit, FDA Panel”
